Abstract. Developing combination drug delivery systems (CDDS) is a challenging but necessary task to meet the needs of complex therapy regimes for patients. As the number of multi-drug regimens being administered increases, so does the difficulty of characterizing the CDDS as a whole. We present a single-step method for quantifying three model therapeutics released from a model hydrogel scaffold using high-performance liquid chromatography (HPLC). Poly(ethylene glycol) dimethacrylate (PEGDMA) hydrogel tablets were fabricated via photoinitiated crosslinking and subsequently loaded with model active pharmaceutical ingredients (APIs), namely, porcine insulin (PI), fluorescein isothiocyanate-labeled bovine serum albumin (FBSA), prednisone (PSE), or a combination of all three. The hydrogel tablets were placed into release chambers and sampled over 21 days, and APIs were quantified using the method described herein. Six compounds were isolated and quantified in total. Release kinetics based on chemical properties of the APIs did not give systematic relationships; however, PSE was found to have improved device loading versus PI and FBSA. Rapid analysis of three model APIs released from a PEGDMA CDDS was achieved with a direct, single-injection HPLC method. Development of CDDS platforms is posited to benefit from such analytical approaches, potentially affording innovative solutions to complex disease states.
INTRODUCTION
In the field of multi-drug therapy regimens, single administration of combination drug therapy has been a staple approach to both enhance therapeutic synergy and patient compliance for improved treatment outcomes. In practice, combination therapy has been routinely prescribed as a single, non-controlled dose via conventional administration routes. Categorically, the most recognized example of combination therapy is the oral dosage form of two small molecules. These include marketed products such as Dyazide (triamterene and hydrochlorothiazide for hypertension), Augmentin (amoxicillin and clavulanic acid as an antibiotic), and Sinemet (carbidopa and levodopa for Parkinson's dopamine replacement) (1). While these precedents have shown increased efficacy, enhanced patient compliance, and improved outcomes relative to their respective monotherapies, the development of more sophisticated combination therapies remains an elusive goal for researchers and clinicians alike.
Combination Drug Delivery Systems
Drug delivery systems are commonly used for the delivery of single therapeutic agents, but further development to deliver "cocktails" of drugs is needed (2) . Two horizons for combination drug delivery systems (CDDSs) are to independently control release of the given active pharmaceutical ingredients (APIs) and the capacity to concurrently administer both small and macromolecule therapeutics. Examples of disease states that demand a combined, controlled dose of a small molecule and protein therapeutic include melanoma, leukemia, rheumatoid arthritis, multiple sclerosis, anemia, and hepatitis C (3) (4) (5) (6) (7) (8) . Thus, an emerging class of CDDSs with such capability is envisioned to expand the therapeutic efficacy of combination therapy as a whole.
An implicit consequence for escalating the complexity of drug delivery systems and the number of administered APIs is the analytical challenge of quantifying delivery rates of multiple therapeutics from a device or delivery system. While single-component systems can be analyzed with routine, singlepass methods such as spectrophotometry and protein detection kits, multi-component systems require more intricate study. Recent interesting work into the development and characterization of CDDSs has readily exemplified such a heightened need (9) (10) (11) (12) (13) (14) . Of the analysis strategies considered in meeting this challenge, we selected analytical high-performance liquid chromatography (HPLC) for isolation of the model APIs and quantification by UV absorbance. Although HPLC is routinely used in such characterization settings, our goal for a single-injection method was nonetheless compounded by the varying properties of the selected APIs and additional interference with the CDDS components themselves (Table I) .
CDDS Components
Poly(ethylene glycol) (PEG) was selected as the material for the CDDS device due to its known advantages of low immunogenicity, high biocompatibility, ease of functionalization, and FDA approval status (13, (15) (16) (17) . Specifically, we employed the bifunctionalized poly(ethylene glycol) dimethacrylate (PEGDMA) monomer in our CDDS fabrication (Fig. 1a) . Previous work has demonstrated its utility in the fabrication of three-dimensional, microtopographical devices (18, 19) . Polymerization of the dimethacrylate groups was afforded by photoinitiated crosslinking with 2,2-dimethoxy-2-phenylacetophenone (DMPA) as a free radical source (Fig. 1b, left) . A third reagent in the fabrication process was 1-vinyl-2-pyrrolidinone (VPY), utilized as a stabilizer and interfacial solvent for DMPA (Fig. 1b, right) . All three of these components have overlapping spectrophotometric absorbance ranges and interfere with commonly used quantification techniques (Table I) . For example, VPY is a reducing agent and interferes with many colorimetric detection assays, and the methacrylate group of the PEGDMA interferes with most spectroscopic quantification techniques due to its high UV absorbance between 200 and 250 nm. Additionally, these system components have a considerable breadth of hexanewater partitioning, making liquid-liquid extraction prior to analysis difficult. The applicable HPLC method we hoped to achieve would be required to isolate all of these CDDS components, while resolving each model API to an independent retention time (RT).
Model APIs
Selection of model APIs was based on the complexity previously cited as an emerging horizon for combination therapy. We aspired to track both small molecule and protein therapeutics in a combination release assay from solid PEGDMA delivery constructs (20) . Additionally, we included a second protein therapeutic for three model APIs in all: porcine insulin (PI), fluorescein isothiocyanate bovine serum albumin (FBSA) and prednisone (PSE). Moreover, the APIs investigated in this work were chosen for their clinical relevance, to explore the effects of construct loading, and to deliver APIs of varying sizes and hydrophobicities. The specific combination of APIs to be delivered in the aforementioned model could be varied depending on the desired application.
PSE, the small molecule, was chosen for its regular application as an immunosuppressant with other protein immunomodulators, such as interferon alpha variants (21) . Two macromolecules were included to investigate the relative differences that molecular weight and hydrophobicity imparted on release behavior from the PEGDMA CDDS of our study. FBSA and PI with molecular weights of 66 and 5.8 kDa, respectively, had hydrophobicities of approximately −0.395 (FBSA) and 0.218 (PI). This roughly corresponds to a tenfold difference in molecular weight and fourfold difference in hydrophobicities (22) . After the hydrogel tablets were crosslinked, they were placed into "loading solutions" containing high concentrations of the APIs and loaded over 72 h.
MATERIALS AND METHODS

Materials
PEGDMA (M N =750), fluorescein isothiocyanate bovine serum album (FBSA or FITC-BSA), 1-vinyl-2-pyrrolidinone (VPY), 2,2-dimethoxy-2-phenylacetophenone (DMPA) of ACS grade, PSE, and insulin (PI, porcine pancreas, lyophilized powder) were all obtained from Sigma, USA, and used without further purification.
Standard Solutions
Phosphate-buffered saline (PBS) was purchased from VWR at a concentration of 10× and diluted tenfold to a final concentration of 1× PBS (137 mM NaCl, 2.7 mM KCl, 10 mM phosphate buffer). The photoinitiator solution was made by dissolving 2,2-dimethoxy-2-phenylacetophenone into 1-vinyl-2-pyrrolidinone to make a 100 mg/mL solution. Standards of PEGDMA, FBSA, VPY, and DMPA were prepared in ranges of 0.1-500 μg/mL in PBS.
HPLC Equipment
A LaChrom Elite® high-performance liquid chromatography system (Hitachi; USA) equipped with an L-2455 diode array detector was utilized for continuous absorbance measurement from 190 to 400 nm during analysis. Stationary phase was afforded with a Luna 5 μm C18(2) 100A, 250× 4.6 mm (Phenomenex Inc.; Torrance, CA), enclosed in a L-2300 column oven equilibrated at 25°C. HPLC grade water (product #JT4218-3), acetonitrile (product #EM-AX0145-1), isopropanol (product #EMD-PX1835-5), and trifluoroacetic acid (TFA, product #EM-TX1276-0004) were purchased from VWR and premixed into three solvent reservoirs prior to use. Solvent A was 100 % water, solvent B was 100 % acetonitrile, and solvent C was a 2:1 (v/v) mixture of isopropanol and acetonitrile. TFA was added to solvents A and B at 0.1 % (v/v) and solvent B at 0.08 % (v/v). The mobile phase eluded at 1 mL/min beginning at 70 % solvent A and 30 % solvent B, increasing to 90 % solvent B and 10 % solvent A from 0 to 21 min. From 21.1 to 30 min, a 100 % solvent C phase was utilized to detect any remaining proteinaceous material adhering to the small-pore column. Finally, the column was re-equilibrated to its starting composition of 70 % solvent A and 30 % solvent B from 30.1 to 35 min.
Hydrogel Tablet Fabrication
PEGDMA tablets were prepared as follows: Hydrogel tablets were made by pipetting 200 μL of a pre-polymer solution containing 50 % PEGDMA, 42 % PBS, and 8 % photoinitiator (v/v) into wells of a 48-well plate. The prepolymer solution was cross-linked for 5 min at 99 J and 365 nm in a UV-box (UVITEC, CL508-BL, UK) and then placed in a vacuum oven for 60 min at 50°C, forming hydrogel tablets. After dehydrating, the tablets were removed from their wells and placed into a loading buffer. After 96 h of loading at 23°C, the tablets were rinsed with PBS, and the wash was collected and tested for API presence. After rinsing, the tablets were placed into 3 mL of elution buffer (fresh PBS) in 5 mL microfuge tubes and shaken at 37°C. Every 72 h, the full volume of liquid was removed from the tubes, analyzed using HPLC, and replaced with 3 mL of fresh PBS.
RESULTS AND DISCUSSION
Characterization of the release kinetics proved challenging due to multiple factors, particularly interactions between the hydrogel components and the APIs. The separation efficacy of assorted components of the hydrogel system is displayed in Fig. 2a . The peaks in time order were: (1) solvent front (RT=3.6 min), (2) VPY (RT=5.2 min), (3) PI (RT=7.7 min), (4) PSE (RT=9.4 min), (5) FBSA (RT= 11.3 min), (6) PEGDMA (RT = 14.4 min), and (7) DMPA (RT=20.1 min). The retention times shown with all components present were in agreement with retention times of components run individually. The three-dimensional plot (Fig. 2b ) exhibits baseline resolution for each peak across all wavelength absorbances. While each component has well-resolved peaks to the baseline at the 220 nm channel, three-dimensional plotting aids in corroborating entity identification. The chemical properties, retention times, and mobile phase composition at RT are shown in Fig. 2c . The sensitivity limits and linear calibration ranges of the method are plotted in Fig. 3 . The maximum linear detection rages (with units of micrograms per milliliter) are comparable to many commonly used assays and are 2.5-500 for PEGDMA, 1-500 for FBSA, 1-200 for PI, 0.5-200 for PSE, 0.25-10 for VPY, and 1-250 for DMPA.
As a platform analytical technique, HPLC is readily capable of separating a diverse set of molecules in given parallel steps and allows for collection of individual components for further analysis. However, the high number of molecular entities within the system significantly increased the difficulty of developing a viable method. A variety of HPLC columns and methods were attempted, including size exclusion, but ultimately, the long carbon chain and small pore size proved most adept. The developed method effectively separated all six components, and furthermore, additional entities can be isolated with modifications of mobile phase composition. The release kinetics of the APIs are displayed in Fig. 4 and were fit to equations of mass released= 100 %× (1-exp(t/t 1/2 )) for each respective API. The delivery half-lives and total mass eluted for porcine insulin, FBSA, and prednisone are 0.1, 1.7, and 3.6 days and 11.9, 13.9, and 64.8 μg, respectively. No apparent trend in release rate versus molecular weight was seen; however, PSE was found to have improved device loading versus PI and FBSA. Ultimately, the hydrogel itself is envisioned to tune the release of therapeutics with rapid feedback from our single-pass technique.
As a model CDDS platform, the studied compounds provide a general approach for analysis of a photo-crosslinkable PEGDMA device. Substituting other model APIs into each compound class would provide a breadth of tunable prototypes for controlled release, biodegradation, and morphological effect studies. In a similar fashion, the analysis method can be tuned for these substitutions with varying percentages of mobile phase during chromatography. The method presented utilized a UV detector to identify the isolated components which allowed for unique fingerprinting of the APIs and wavelength selection to achieve optimum detection sensitivity. However, the UV detector can be replaced or used in tandem with a refractive index detector to characterize systems and APIs without chromophores.
CONCLUSION
The need for a single-pass, quantitative analysis of multiagent APIs for combination therapies is a growing demand in the field of drug delivery systems. As the number of emerging scaffolds and therapeutics increases, so does the need to develop efficient characterization techniques to aid in CDDS development. The method presented exemplifies an approach to this challenge, providing an efficient separative and quantitative means to analyze a PEG-based delivery device and kit of model therapeutics. Further versatility was achieved by resolving device components used in scaffold fabrication which is important to the clinical application of the CDDS. Total characterization in a single-injection HPLC technique presents a valuable and productive resource for affording innovative solutions in CDDS evolution.
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